Metagenomi to Present New Preclinical Data from Novel Gene Editing Programs at the 24th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

April 27, 2021 |

2 min read

Metagenomi, a gene editing company, today announced that it will present findings from its novel gene editing programs at the 24th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), which will be held virtually May 11–14, 2021.

EMERYVILLE, Calif.--(BUSINESS WIRE)-- Metagenomi, a gene editing company, today announced that it will present findings from its novel gene editing programs at the 24^th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), which will be held virtually May 11–14, 2021.

The Metagenomi team will have a total of five presentations during this year’s meeting. The presentations will feature new preclinical data related to Metagenomi’s novel CRISPR-associated gene editing systems, their novel CRISPR-associated transposases (CAST) system, as well as data related to the utility of these systems for ex vivo and in vivo gene editing applications and cell therapy development. Abstracts can be found on the ASGCT website: https://annualmeeting.asgct.org/.

Presentation Details:

		Title: Novel CRISPR-associated Transposase Systems for Targeted DNA Integration
		Presenting Author: Daniela S. A. Goltsman, Ph.D.
		Abstract Number: 203
		Session Title: Base Editing and Gene Editing Approaches
		Date & Time: Friday, May 14, 12:45 p.m. ET

		Title: Novel CRISPR-associated Gene-editing Systems Discovered in Metagenomic Samples Enable Efficient and Specific Genome Engineering for Cell Therapy Development
		Presenting Author: Gregory J. Cost, Ph.D.
		Abstract Number: 206
		Session Title: Base Editing and Gene Editing Approaches
		Date & Time: Friday, May 14, 1:30 p.m. ET

Poster Details:

		Title: A Novel CRISPR Associated Type V Editing System Derived from Metagenomic Samples with Potent Activity in Liver Cells
		Presenting Author: Morayma M. Temoche-Diaz, Ph.D.
		Abstract Number: 409
		Session Title: Gene Targeting and Gene Correction
		Date & Time: Tuesday, May 11, 8:00 a.m. ET

		Title: Expanding PAM Recognition of CRISPR-associated Endonucleases by Domain Engineering
		Presenting Author: Aaron Lin, Ph.D.
		Abstract Number: 376
		Session Title: Gene Targeting and Gene Correction
		Date & Time: Tuesday, May 11, 8:00 a.m. ET

		Title: Novel Families of CRISPR Systems Enriched in Small Effectors with Genome Editing Capability
		Presenting Authors: Lisa Alexander, Ph.D.
		Abstract Number: 393
		Session Title: Gene Targeting and Gene Correction
		Date & Time: Tuesday, May 11, 8:00 a.m. ET

About Metagenomi

At Metagenomi, we are accelerating innovation in cell and gene therapy with a wave of proprietary CRISPR-based systems to accurately edit DNA where current technologies cannot. Our metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. We adapt and forge these naturally evolved systems into powerful therapeutic tools that can be leveraged by partners and fuel our own pipeline of potentially curative medicines. Our goal is to revolutionize gene editing and unlock its power for the benefit of patients around the world. For more information, please visit https://metagenomi.co/